This Week's Fund Closings

Jan 13 2006 | 8:30pm ET

• Private equity firm Aisling Capital has closed it its life sciences fund, Aisling Capital II, With $550 million in commitments.  The New York-headquartered Aisling, which has $1 billion in assets under management, was spun-out of Perseus-Soros Management. Aisling will invest primarily in life science companies that are developing biopharmaceutical products and creating businesses based on advanced life science technologies. Dennis Purcell, senior managing director of Aisling, said in a release, "we continue to believe that opportunities exist in all areas of the life sciences industry and will implement a strategy similar to the first fund."


In Depth

Fund Focus: Don’t Call K1T Capital A ‘Trend Follower’

Jul 10 2014 | 10:39am ET

You may call K1T Capital many things—systematic, quant-based, hedge fund—but...

Lifestyle

RenTech Founder Donation Establishes Quantitative Biology Institute

Jul 8 2014 | 5:19am ET

James Simons used math to make his fortune, and he’s dedicating some of it to...

Guest Contributor

As Hedge Funds Go Retail, Communications Is Key

Jul 2 2014 | 6:56am ET

The past two years have seen an explosion in the number of hedge fund managers rolling...

 

Sponsored Content

    Northern Trust Helps Hedge Funds Navigate Derivatives Regulations

    Jul 8 2014 | 10:48am ET

    The surge in derivatives regulation is among the most complex challenges facing the financial services industry today. Northern Trust’s Joshua Satten recently spoke with FINalternatives to share insights into the challenges presented by new regulation and explore how the industry is responding. Read more…

Service Providers


Publisher's Note